Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.61 |
| ▸ | AOC3 | Q16853 | 7/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1295513 | 1.00 | LMNA (0.67) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| SCHEMBL348229 | 1.00 | LMNA (0.67) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| SCHEMBL28617318 | 1.00 | LMNA (0.67) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| Phenylpropanol SCHEMBL9863274 | 0.94 | LMNA (0.79) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| Acetic Acid SCHEMBL29265549 | 0.92 | LMNA (0.57) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| Acetic Acid SCHEMBL29265550 | 0.92 | LMNA (0.57) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| Fenipentol SCHEMBL11351770 | 0.88 | LMNA (0.64) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| Fenipentol SCHEMBL21837 | 0.88 | LMNA (0.64) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| Fenipentol SCHEMBL11573151 | 0.88 | LMNA (0.64) | LMNARIPK1AOC3KDM4EL3MBTL1 | |
| SCHEMBL21633858 | 0.87 | LMNA (0.48) | LMNARIPK1AOC3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| WO-2024190722-A1 | METHOD FOR IDENTIFYING OPTICAL ISOMER OF LOW-MOLECULAR-WEIGHT COMPOUND | 国立大学法人大阪大学 | 2024-09-19 | — | — | WO | disclosed |
| CN-115745764-B | Preparation method of milbelin intermediate | 重庆华森制药股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO HEALTH, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230194486-A1 | QUANTITATIVE CHIRALITY AND CONCENTRATION SENSING OF CHIRAL ANALYTES USING A RELAY ASSAY | NATIONAL SCIENCE FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| CN-115745764-A | Preparation method of milobalin intermediate | 重庆华森制药股份有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2021225688-A1 | QUANTITATIVE CHIRALITY AND CONCENTRATION SENSING OF CHIRAL ANALYTES USING A RELAY ASSAY | GEORGETOWN UNIVERSITY (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2000064911-A1 | LIGANDS FOR METABOTROPIC GLUTAMATE RECEPTORS | GEORGETOWN UNIVERSITY (US) | 2000-11-02 | — | — | WO | disclosed |
| EP-0603278-A1 | INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-29 | — | — | EP | disclosed |
| WO-1993005019-A1 | INDOLE DERIVATIVES AS 5-ALPHA-REDUCTASE INHIBITOR | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-18 | — | — | WO | disclosed |
| US-4983739-A | Optically active styrene compounds | CIBA-GEIGY CORPORATION (US) | 1991-01-08 | — | — | US | disclosed |
| US-4954592-A | Optically active styrene derivatives, polymers obtained from these, complexes with iridium(I) and their use | CIBA-GEIGY CORPORATION (US) | 1990-09-04 | — | — | US | disclosed |
| US-4904790-A | Optically active styrene compounds substituted by a pyridinyl group | CIBA-GEIGY CORPORATION (US) | 1990-02-27 | — | — | US | disclosed |
| US-4891412-A | Optically active styrene derivatives, polymers obtained from these, complexes with iridium(I) and their use | CIBA-GEIGY CORPORATION (US) | 1990-01-02 | — | — | US | disclosed |
| US-4800224-A | Optically active styrene derivatives, polymers obtained from these, complexes with iridium(I) and their use | CIBA-GEIGY CORPORATION (US) | 1989-01-24 | — | — | US | disclosed |
| EP-0251994-A1 | Optically active styrene derivatives, polymers therefrom, complexes with iridium (I) and their use | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12336981-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NNT | LMNA 860/4885RIPK1 1927/4885AOC3 2433/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LMNA 1579/4885RIPK1 1529/4885AOC3 2579/4885 |
| US-11547701-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LMNA 923/4885RIPK1 1817/4885AOC3 2447/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LMNA 1579/4885RIPK1 1529/4885AOC3 2579/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | LMNA 923/4885RIPK1 1817/4885AOC3 2447/4885 |
| US-20230346753-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | LMNA 1579/4885RIPK1 1529/4885AOC3 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.